Physician profile
Beverly Wilson
NPI 1467703157
$289.93
in general payments reported to CMS, 2019-2025
12 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.59 · 2023: $33.22 · 2024: $104 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48.26 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $48.18 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $39.12 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $21.49 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $19.00 | 2025 | Thinprep 2000 Processor, Aptima |
| Glaxosmithkline, LLC. | $18.73 | 2024 | Shingrix, Arexvy |
| Astellas Pharma US INC | $18.50 | 2024 | Veozah |
| Indivior INC. | $17.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.81 | 2025 | Farxiga |
| Merck Sharp & Dohme LLC | $14.65 | 2025 | Gardasil 9, Capvaxive, M-M-R II |
| Phathom Pharmaceuticals, INC. | $14.04 | 2024 | Voquezna |
| Lilly USA, LLC | $13.60 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.